Trials
3 active
11 in total · 8 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Hypertriglyceridemia, Severe Hypertriglyceridemia
- Main trialPhase 3
- “This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to…”In the company’s words, NCT06822790 on ClinicalTrials.gov
- Other names
- ARO-APOC3
Other drugs for Hypertriglyceridemia
Coming up2
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jul 2028 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | |
| Phase 3Recruiting | Mar 2029 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | |
| Phase 3Completed | 29 Apr 2024 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | |
| Phase 3Completed | 1 Jun 2026 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | |
| Phase 3Completed | 12 Jun 2026 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | |
| Phase 3Completed | 17 Jun 2026 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | |
| Phase 2Completed | 10 Feb 2023 | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia | |
| Phase 2Completed | 9 Mar 2023 | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia | |
| Phase 2Completed | 22 Sep 2025 | Study of ARO-APOC3 in Adults With Dyslipidemia | |
| Phase 1Completed | 11 Feb 2021 | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) | |
| Phase 3Authorised | not given | Open-Label Study to Evaluate the Activity, Pharmacokinetics, Pharmacodynamics, And Safety of Plozasiran in Adolescents (Age 12 to <18 Years) With Familial Chylomicronemia Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026